

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

### Review Proposal Project

#### NICE Technology Appraisal no. 187; Infliximab and adalimumab for the treatment of Crohn's disease

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Abbott Laboratories (adalimumab)</li> <li>• Schering Plough (infliximab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Bladder and Bowel Foundation</li> <li>• Chinese National Healthy Living Centre</li> <li>• Colostomy Association</li> <li>• Counsel and Care</li> <li>• Crohn's and Colitis UK</li> <li>• Equalities National Council</li> <li>• IA: Ileostomy and Internal Pouch Support Group</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Ostomy Lifestyle Centre</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Coloproctology of Great Britain and Ireland</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Society of Gastroenterology</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (azathioprine, metronidazole, sulfasalazine)</li> <li>• Almus Pharmaceuticals (metronidazole, sulfasalazine)</li> <li>• AstraZeneca UK (budesonide)</li> <li>• Dr Falk Pharma UK (mesalazine, budesonide)</li> <li>• Ferring Pharmaceuticals (mesalazine)</li> <li>• Forest Laboratories UK (prednisolone)</li> <li>• GlaxoSmithKline (azathioprine, mercaptopurine)</li> <li>• Kent Pharmaceuticals (azathioprine, mesalazine, sulfasalazine)</li> <li>• Mayne Pharma (methotrexate)</li> </ul>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society of Great Britain</li> <li>• Royal Society of Medicine</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• Society and College of Radiographers</li> <li>• British Institute of Radiology</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Croydon</li> <li>• NHS North Somerset</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• Novartis Pharmaceuticals (ciclosporin)</li> <li>• Pfizer (methotrexate and sulfasalazine)</li> <li>• Procter and Gamble Pharmaceuticals (UK) (mesalazine)</li> <li>• Sandoz (mesalazine, metronidazole)</li> <li>• Sanofi-Aventis (sodium cromoglicate, metronidazole)</li> <li>• Shire Pharmaceuticals (balsalazide sodium, mesalazine)</li> <li>• Teva UK (azathioprine, mesalazine, methotrexate, sulfasalazine)</li> <li>• UCB Pharma (olsalazine sodium)</li> <li>• Winthrop Pharmaceuticals UK (metronidazole)</li> <li>• Wockhardt UK (methotrexate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• CORE - The Digestive Disorders Foundation</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme</li> <li>• Tbc</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guideline Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• none</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

**Definitions:**Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, the *British National Formulary*, and the British Medical Association).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.